By Fineline Cube Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s New Drug Application for Category 1 innovative drug TQB3909 Tablet has been submitted to and accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have received at least one prior systemic therapy, including a BTK inhibitor.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | CDE/NMPA (China) |
| Application Type | Category 1 innovative drug NDA |
| Product | TQB3909 Tablet (BCL-2 inhibitor) |
| Indication | Relapsed/refractory CLL/SLL after ≥1 prior systemic therapy (including BTK inhibitors) |
| Development Status | Phase II registrational trial completed, NDA accepted |
| Innovation Classification | Independently developed Category 1 innovative drug |
Drug Mechanism & Scientific Profile
- Target: BCL-2 protein (anti-apoptotic regulator)
- Mechanism of Action:
- Binds to BCL-2 protein, releasing pro-apoptotic proteins (BAK, BAX, BAD)
- Promotes mitochondrial cytochrome c release
- Induces phosphatidylserine externalization
- Stimulates caspase-3/7 activity and caspase-3/9 cleavage
- Ultimately triggers programmed cell death (apoptosis) in malignant B-cells
- Therapeutic Innovation: First domestically developed BCL-2 inhibitor in China for CLL/SLL
- Development Origin: Independently developed by CTTQ (Sino Biopharmaceutical subsidiary)
Clinical Evidence – Phase II Registrational Trial
- Study Design: Single-arm, open-label, multicenter Phase II trial
- Population: Patients with relapsed or refractory CLL/SLL who received ≥1 prior systemic therapy (including BTK inhibitors)
- Primary Endpoints: Efficacy and safety assessment
- Key Results:
- Significant efficacy demonstrated in heavily pre-treated patient population
- Manageable safety profile with acceptable tolerability
- Clinical benefit advantage compared to currently available treatment options in China
- Regulatory Strategy: Accelerated approval pathway based on single-arm Phase II data for high-unmet-need indication
Market Context & Competitive Landscape
- CLL/SLL Burden: CLL is the most common adult leukemia in Western countries; growing incidence in China
- Treatment Gap: Limited options for patients progressing after BTK inhibitor therapy
- Current Standard: BTK inhibitors (ibrutinib, zanubrutinib) as first-line; limited second-line options in China
- Competitive Advantage: TQB3909 addresses critical unmet need in BTK inhibitor-resistant/refractory population
- Market Opportunity: First-in-class potential in Chinese market for BCL-2 inhibition in CLL/SLL
Strategic Implications for Sino Biopharmaceutical
- Oncology Portfolio Expansion: Strengthens position in hematological malignancies
- Innovation Validation: Demonstrates capability for complex target class (BCL-2) drug development
- Commercial Potential: High-value orphan indication with premium pricing potential
- Global Ambition: Success in China may support future international regulatory submissions
- Pipeline Catalyst: Validates CTTQ’s independent R&D capabilities for future innovative programs
Forward Development & Commercial Outlook
- Regulatory Timeline: Priority review possible given high unmet medical need
- Market Access: Expected inclusion in national reimbursement negotiations upon approval
- Physician Education: Required for optimal patient selection and management
- Combination Potential: Future studies may explore combinations with other targeted agents
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical trial results, and commercial potential. Actual outcomes may differ due to risks including final regulatory decisions, competitive dynamics, and market acceptance.-Fineline Info & Tech